Mallinckrodt agrees to $35 million oxycodone settlement

Pharmaceutical manufacturer Mallinckrodt has reached a $35 million settlement with the U.S. Drug Enforcement Administration and U.S. Attorneys’ offices in Michigan and New York, the U.S. Department of Justice announced in a news release.

The settlement came in response to allegations that the company violated parts of the Controlled Substances Act specifically involving its monitoring program for drugs it sold.

Mallinckrodt, which has its U.S. headquarters in St. Louis, “did not meet its obligations to detect and notify DEA of suspicious orders of controlled substances such as oxycodone, the abuse of which is part of the current opioid epidemic,” according to the news release.

While the company denies that it broke the law in failing to report suspicious orders that were “unusual in their frequency, size or other patterns,” it has entered into an agreement with the DEA that will see it use collected customer information to dig deeper into the supply chain and “know your customer’s customer,” according to the release.


Tags:, , , , , ,

Leave a Reply

Have you heard?

Missouri Business Alert is participating in CoMoGives2019!

Find out how we plan to use your gift to enhance training and programming for our students